Source: http://www.aoa.org/x5625.xml
Optos
Optos is a GOLD level sponsor of the American Optometric Association.
|
Optos plc is a leading and rapidly growing medical technology company for the design, development, manufacturing and marketing of devices that image the retina. Optos' platform technology delivers a high-resolution image of up to 200 degrees or approximately 82 percent of the retina in a single capture in a quarter of a second.
Optos has commercialized a full range of complementary retinal imaging devices: P200 is concentrated on wellness screening; P200C in the advanced clinical optometry and ophthalmology markets; P200MA supports retinal specialists through an advanced medical angiography procedure. All three devices provide practitioners with the benefit of an ultra wide-field view of the retina or, alternatively, a maximized resolution image of the central pole-each facilitating the early detection and management of disorders and diseases evidenced in the retina, such as glaucoma, diabetic retinopathy and age-related macular degeneration as well as evidence of non-eye or systemic diseases such as diabetes, hypertension and certain cancers. Optos' technology provides an unequalled combination of wide-field retinal imaging, speed and convenience for both practitioner and patient and can help save sight and save lives.
Optos recently introduced the latest version of its proprietary operating software - V2® Vantage Dx, which provides added functionality and features, and is available with all new devices and to current Optos partners. V2® Vantage Dx with Exact Disc™ Nerve Enhancement provides a natural presentation of the nerve head. Also, there are new features within 3D Wrap™ Patient Orientation Tool that include a refractive error capability that enables the doctor to demonstrate the effects of refractive error and how this affects vision, providing greater patient education. Another important addition includes a proprietary set of software tools that introduce a new workflow that promotes high patient acceptance rates.
These latest enhancements to Optos' operating software follow a series of updates including the addition of the optomap® plus Medical Retinal Exam, which is eligible for reimbursement under fundus photography (92250), and V2® Vantage with features such as ResMax™ High Resolution for the Central Pole, 3D Wrap™ Patient Orientation Tool and Targeted Ophthalmoscopy, which simulates the view of a BIO exam, among others.
Optos' newest device, the P200C, is designed to meet the need for more exacting clinical imaging capabilities within practices that have a high percentage of patients with ocular disease. The P200C delivers both ultra wide-field and ultra high-resolution images to facilitate disease management and clinical analysis. Improved automated eye steering promotes easy multiple image acquisition from a single patient to capture far-peripheral abnormalities, in some cases reaching the ora serrata.
Optos' unique partnership program provides a wealth of technical, educational and marketing resources, including on-site staff and physician training, best practice protocols, patient education materials and marketing outreach programs, as well as continued maintenance and customer support.
Optos plc is headquartered in Dunfermline, Scotland, and was admitted to the Main Market of the London Stock Exchange on Feb. 15, 2006, trading under the symbol OPTS. Optos' North American headquarters is based in Marlborough, Mass. For more information, visit www.optos.com.